Janssen to use mobile platform for trials

11 October 2017

The pharma unit of US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced that it is embarking on a world first for the drug industry.

Janssen says that it has developed a novel mobile technology platform designed to make clinical studies more efficient and that its use of this will represent the first usage of a comprehensive technology toolset like this in a global pharmaceutical clinical trial.

The Integrated Smart Trial & Engagement Platform (iSTEP) has been developed to automate investigational product supply and data management in clinical trials and is being made available for industry-wide use through a collaboration with the Indian information technology giant Tata Consultancy Services (NSE: TCS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK